<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073589</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1901</org_study_id>
    <secondary_id>2019-002102-40</secondary_id>
    <nct_id>NCT04073589</nct_id>
  </id_info>
  <brief_title>Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-label, Parallel-group Trial to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Different Single Subcutaneous Dose Levels of Efgartigimod Co-administered With rHuPH20 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate the pharmacodynamic (PD), pharmacokinetic (PK),&#xD;
      safety, tolerability, and immunogenicity of efgartigimod co-administered with rHuPH20, and to&#xD;
      measure the time to inject the full dose of investigational medicinal product (IMP) of&#xD;
      different dose levels of efgartigimod co-administered with a fixed concentration of rHuPH20&#xD;
      by the subcutaneous (SC) route of administration in healthy adult male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IgG levels of four different subcutaneous dose levels</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentrations (Cmax) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentrations (Tmax) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Curve (AUC) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (serious) adverse events</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anti-drug antibodies</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to administer the different doses</measure>
    <time_frame>Up to 11 weeks, from study start until the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of Dose D</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARGX-113 with rHuPH20</intervention_name>
    <description>subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>efgartigimod with rHuPH20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male, between 18 to 70 years of age&#xD;
&#xD;
          2. Subject is healthy&#xD;
&#xD;
          3. Subject has a body mass index (BMI) between 18 kg/m2 to 30 kg/m2&#xD;
&#xD;
          4. Subject is willing and able to understand the purpose and risks of the trial and&#xD;
             provide signed and dated informed consent,&#xD;
&#xD;
          5. Others as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous participation in clinical trials with efgartigimod and/or any products with&#xD;
             rHuPH20.&#xD;
&#xD;
          2. Known hypersensitivity to IMP ingredients or history of a severe allergic or&#xD;
             anaphylactic reaction to any drug as determined by the investigator.&#xD;
&#xD;
          3. Known seropositivity or positive test at screening for an active viral infection with&#xD;
             Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV).&#xD;
&#xD;
          4. Known clinically relevant immunological disorders.&#xD;
&#xD;
          5. Known history or any symptom of clinically significant illness in the 6 months before&#xD;
             IMP administration.&#xD;
&#xD;
          6. Others as defined in the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Guglietta, MD</last_name>
    <role>Study Director</role>
    <affiliation>argenx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

